Global healthcare company Abbot has announced that it has conducted an assessment of the Omicron variant.
New Delhi, Dec 3: Global healthcare company Abbot has announced that it has conducted an assessment of the Omicron variant and it is confident that the rapid and PCR tests can detect the virus.
Abbott is currently manufacturing more than 100 million Covid-19 rapid and PCR tests a month to help support increased need for testing around the globe. "We are actively collecting real-world samples and using viral cultures to verify that our tests continually detect circulating strains because we know how important it is that our tests can detect new variants regardless of where they are found," it added.
Through Abbott's Pandemic Defense Coalition, a network of research, academic and public health collaborators strategically placed around the world that are actively sequencing viruses to look for the next viral threat including COVID variants.
"We are actively engaged with our partner in South Africa on Omicron. We also have an entire team of Abbott scientists dedicated to monitoring Covid-19 variants. To date, we have carefully analyzed over 1.4 million sequences from 63 different variants and none have impacted the ability of our diagnostic tests to detect the virus. And as soon as the Omicron sequence was made available, our scientists worked non-stop to evaluate it and determined the mutations would not impact the ability of our rapid and PCR tests to detect it," Abbot said.